<DOC>
	<DOC>NCT01721746</DOC>
	<brief_summary>The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel</brief_summary>
	<brief_title>A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Men &amp; women â‰¥ 18 years of age Eastern Cooperative Oncology Group (ECOG) performance status (PS) 01 Histologically confirmed Stage III (unresectable)/Stage IV melanoma Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria Objective evidence of disease progression (clinical or radiological) during or after at least 1 (V600 Wildtype) or at least 2 (V600 mutation positive) prior treatment regimens Pretreatment fresh core, excision or punch tumor biopsy Archival Formalinfixed paraffinembedded (FFPE) tumor material if available Any treatment in a BMS936558 (Nivolumab) trial Subjects with condition requiring systemic treatment with either corticosteroids (&gt; 10mg daily prednisone/equivalent) or other immunosuppressive medications within 14 days of study drug administration Active, known or suspected autoimmune disease Unknown BRAF status Active brain metastasis or leptomeningeal metastasis Ocular melanoma Prior therapy with anti programmed death1 (antiPD1), anti programmed deathligand 1 (antiPDL1) or antiprogrammed deathligand 2 (antiPDL2)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>